Amygdalin Regulates Apoptosis and Adhesion in Hs578T Triple-Negative Breast Cancer Cells
Amygdalin, D-mandelonitrile-β-D-glucoside-6-β-glucoside, belongs to aromatic cyanogenic glycoside group derived from rosaceous plant seed. Mounting evidence has supported the anti-cancer effects of amygdalin. However, whether amygdalin indeed acts as an anti-tumor agent against breast cancer cells i...
Saved in:
| Published in | Biomolecules & therapeutics Vol. 24; no. 1; pp. 62 - 66 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | English |
| Published |
Korea (South)
The Korean Society of Applied Pharmacology
01.01.2016
한국응용약물학회 |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2005-4483 1976-9148 1976-9148 2005-4483 |
| DOI | 10.4062/biomolther.2015.172 |
Cover
| Abstract | Amygdalin, D-mandelonitrile-β-D-glucoside-6-β-glucoside, belongs to aromatic cyanogenic glycoside group derived from rosaceous plant seed. Mounting evidence has supported the anti-cancer effects of amygdalin. However, whether amygdalin indeed acts as an anti-tumor agent against breast cancer cells is not clear. The present study aimed to investigate the effect of amygdalin on the proliferation of human breast cancer cells. Here, we show that amygdalin exerted cytotoxic activities on estrogen receptors (ER)-positive MCF7 cells, and MDA-MB-231 and Hs578T triple-negative breast cancer (TNBC) cells. Amygdalin induced apoptosis of Hs578T TNBC cells. Amygdalin downregulated B-cell lymphoma 2 (Bcl-2), upregulated Bcl-2-associated X protein (Bax), activated of caspase-3 and cleaved poly ADP-ribose polymerase (PARP). Amygdalin activated a pro-apoptotic signaling molecule p38 mitogen-activated protein kinases (p38 MAPK) in Hs578T cells. Treatment of amygdalin significantly inhibited the adhesion of Hs578T cells, in which integrin α5 may be involved. Taken together, this study demonstrates that amygdalin induces apoptosis and inhibits adhesion of breast cancer cells. The results suggest a potential application of amygdalin as a chemopreventive agent to prevent or alleviate progression of breast cancer, especially TNBC. |
|---|---|
| AbstractList | Amygdalin, D-mandelonitrile-β-D-glucoside-6-β-glucoside, belongs to aromatic cyanogenic glycoside group derived from rosaceous plant seed. Mounting evidence has supported the anti-cancer effects of amygdalin. However, whether amygdalin indeed acts as an anti-tumor agent against breast cancer cells is not clear. The present study aimed to investigate the effect of amygdalin on the proliferation of human breast cancer cells. Here, we show that amygdalin exerted cytotoxic activities on estrogen receptors (ER)-positive MCF7 cells, and MDA-MB-231 and Hs578T triple-negative breast cancer (TNBC) cells. Amygdalin induced apoptosis of Hs578T TNBC cells. Amygdalin downregulated B-cell lymphoma 2 (Bcl-2), upregulated Bcl-2-associated X protein (Bax), activated of caspase-3 and cleaved poly ADP-ribose polymerase (PARP). Amygdalin activated a pro-apoptotic signaling molecule p38 mitogen-activated protein kinases (p38 MAPK) in Hs578T cells. Treatment of amygdalin significantly inhibited the adhesion of Hs578T cells, in which integrin α5 may be involved. Taken together, this study demonstrates that amygdalin induces apoptosis and inhibits adhesion of breast cancer cells. The results suggest a potential application of amygdalin as a chemopreventive agent to prevent or alleviate progression of breast cancer, especially TNBC. Amygdalin, D-mandelonitrile-β-D-glucoside-6-β-glucoside, belongs to aromatic cyanogenic glycoside group derived from rosaceous plant seed. Mounting evidence has supported the anti-cancer effects of amygdalin. However, whether amygdalin indeed acts as an anti-tumor agent against breast cancer cells is not clear. The present study aimed to investigate the effect of amygdalin on the proliferation of human breast cancer cells. Here, we show that amygdalin exerted cytotoxic activities on estrogen receptors (ER)-positive MCF7 cells, and MDA-MB-231 and Hs578T triple-negative breast cancer (TNBC) cells. Amygdalin induced apoptosis of Hs578T TNBC cells. Amygdalin downregulated B-cell lymphoma 2 (Bcl-2), upregulated Bcl-2-associated X protein (Bax), activated of caspase-3 and cleaved poly ADP-ribose polymerase (PARP). Amygdalin activated a pro-apoptotic signaling molecule p38 mitogen-activated protein kinases (p38 MAPK) in Hs578T cells. Treatment of amygdalin significantly inhibited the adhesion of Hs578T cells, in which integrin α5 may be involved. Taken together, this study demonstrates that amygdalin induces apoptosis and inhibits adhesion of breast cancer cells. The results suggest a potential application of amygdalin as a chemopreventive agent to prevent or alleviate progression of breast cancer, especially TNBC. KCI Citation Count: 2 Amygdalin, D-mandelonitrile-β-D-glucoside-6-β-glucoside, belongs to aromatic cyanogenic glycoside group derived from rosaceous plant seed. Mounting evidence has supported the anti-cancer effects of amygdalin. However, whether amygdalin indeed acts as an anti-tumor agent against breast cancer cells is not clear. The present study aimed to investigate the effect of amygdalin on the proliferation of human breast cancer cells. Here, we show that amygdalin exerted cytotoxic activities on estrogen receptors (ER)-positive MCF7 cells, and MDA-MB-231 and Hs578T triple-negative breast cancer (TNBC) cells. Amygdalin induced apoptosis of Hs578T TNBC cells. Amygdalin downregulated B-cell lymphoma 2 (Bcl-2), upregulated Bcl-2-associated X protein (Bax), activated of caspase-3 and cleaved poly ADP-ribose polymerase (PARP). Amygdalin activated a pro-apoptotic signaling molecule p38 mitogen-activated protein kinases (p38 MAPK) in Hs578T cells. Treatment of amygdalin significantly inhibited the adhesion of Hs578T cells, in which integrin α5 may be involved. Taken together, this study demonstrates that amygdalin induces apoptosis and inhibits adhesion of breast cancer cells. The results suggest a potential application of amygdalin as a chemopreventive agent to prevent or alleviate progression of breast cancer, especially TNBC.Amygdalin, D-mandelonitrile-β-D-glucoside-6-β-glucoside, belongs to aromatic cyanogenic glycoside group derived from rosaceous plant seed. Mounting evidence has supported the anti-cancer effects of amygdalin. However, whether amygdalin indeed acts as an anti-tumor agent against breast cancer cells is not clear. The present study aimed to investigate the effect of amygdalin on the proliferation of human breast cancer cells. Here, we show that amygdalin exerted cytotoxic activities on estrogen receptors (ER)-positive MCF7 cells, and MDA-MB-231 and Hs578T triple-negative breast cancer (TNBC) cells. Amygdalin induced apoptosis of Hs578T TNBC cells. Amygdalin downregulated B-cell lymphoma 2 (Bcl-2), upregulated Bcl-2-associated X protein (Bax), activated of caspase-3 and cleaved poly ADP-ribose polymerase (PARP). Amygdalin activated a pro-apoptotic signaling molecule p38 mitogen-activated protein kinases (p38 MAPK) in Hs578T cells. Treatment of amygdalin significantly inhibited the adhesion of Hs578T cells, in which integrin α5 may be involved. Taken together, this study demonstrates that amygdalin induces apoptosis and inhibits adhesion of breast cancer cells. The results suggest a potential application of amygdalin as a chemopreventive agent to prevent or alleviate progression of breast cancer, especially TNBC. |
| Author | Moon, Aree Lee, Hye Min |
| Author_xml | – sequence: 1 givenname: Hye Min surname: Lee fullname: Lee, Hye Min organization: College of Pharmacy, Duksung Women’s University, Seoul 01369, Korea – sequence: 2 givenname: Aree surname: Moon fullname: Moon, Aree organization: College of Pharmacy, Duksung Women’s University, Seoul 01369, Korea |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26759703$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002060567$$DAccess content in National Research Foundation of Korea (NRF) |
| BookMark | eNp9Uctu1DAUtVARnRa-AAl5ySaD33E2SGFUaKUKpGqQ2FlOcjNjmtjBzlTq3-N0aHksWN3FPY97zzlDJz54QOg1JWtBFHvXuDCGYd5DXDNC5ZqW7Bla0apURUWFPkErRogshND8FJ2l9J0QVVKpXqBTpkpZlYSv0Ld6vN91dnAe38DuMNgZEq6nMM0huYSt73Dd7SG54HHGXCZZ6i3eRjcNUHyGnZ3dHeAPEWya8cb6FiLewDCkl-h5b4cEr37Nc_T148V2c1lcf_l0tamvi1ZwPRe9bqATjFhOuBQceKsr2QgioSMNLVXPZKOJ1MKqSjdSMcsqKyijvVDUWsbP0dujro-9uW2dCdY9zF0wt9HUN9srQ6scisjQ90fodGhG6Frwc7SDmaIbbbx_IP698W6fZe6MyFEt1z15TTH8OECazehSm7-1HsIhmXwv0aWURGfomz-9nkwek8-A6ghoY0gpQm9aN-c0w2LtBkOJWVo2v1s2S8vZY_mZ_8N9lP8f6ydbsK5W |
| CitedBy_id | crossref_primary_10_3389_fphar_2022_1013692 crossref_primary_10_1111_jfbc_13436 crossref_primary_10_2174_1871520620666200120095525 crossref_primary_10_3390_cancers16183131 crossref_primary_10_1080_08923973_2018_1441301 crossref_primary_10_3390_cancers13040882 crossref_primary_10_1016_j_fct_2017_08_001 crossref_primary_10_1007_s11033_020_05782_z crossref_primary_10_2147_IJN_S242359 crossref_primary_10_1142_S0192415X22500586 crossref_primary_10_1002_cbin_12276 crossref_primary_10_1016_j_tice_2024_102443 crossref_primary_10_1155_2020_4372719 crossref_primary_10_1016_j_jep_2020_112717 crossref_primary_10_3390_ijms19010107 crossref_primary_10_3390_cells11081326 crossref_primary_10_3390_ph14090881 crossref_primary_10_1016_j_canlet_2018_08_025 crossref_primary_10_1016_j_jep_2018_11_027 crossref_primary_10_3390_molecules27217591 crossref_primary_10_4103_jasmr_jasmr_27_22 crossref_primary_10_1007_s11033_019_05080_3 crossref_primary_10_5219_791 crossref_primary_10_1002_cam4_2197 crossref_primary_10_1080_07391102_2020_1742792 crossref_primary_10_1016_j_biopha_2020_110940 crossref_primary_10_3389_fphar_2024_1290888 crossref_primary_10_5219_755 crossref_primary_10_1007_s11033_019_04656_3 crossref_primary_10_3923_ijp_2017_488_494 crossref_primary_10_1016_j_toxicon_2023_107200 crossref_primary_10_7717_peerj_9232 crossref_primary_10_2174_2589977513666211202094433 crossref_primary_10_1007_s12033_023_00680_8 crossref_primary_10_1016_j_ijbiomac_2023_124201 crossref_primary_10_1016_j_cbi_2022_110235 crossref_primary_10_3390_biom12101514 crossref_primary_10_1038_onc_2017_298 crossref_primary_10_3390_molecules26082253 crossref_primary_10_1007_s11033_020_05286_w crossref_primary_10_1007_s12272_016_0787_8 crossref_primary_10_1016_j_cmpb_2020_105660 crossref_primary_10_1515_arls_2017_0012 crossref_primary_10_1093_toxres_tfae084 crossref_primary_10_52711_0974_360X_2022_00906 crossref_primary_10_3724_abbs_2022136 crossref_primary_10_3892_ol_2016_4837 crossref_primary_10_3389_fimmu_2024_1464329 crossref_primary_10_1002_adbi_202300025 crossref_primary_10_1080_07391102_2020_1736159 crossref_primary_10_1016_j_tox_2021_153019 crossref_primary_10_3389_fphar_2021_801662 crossref_primary_10_1016_j_fbio_2022_102336 crossref_primary_10_3390_ph13110395 crossref_primary_10_62425_rtpharma_1523732 crossref_primary_10_1016_j_bmc_2016_09_051 crossref_primary_10_1016_j_heliyon_2024_e38673 crossref_primary_10_1038_s41388_021_01758_w crossref_primary_10_1186_s13020_021_00539_7 crossref_primary_10_1080_03601234_2020_1852054 crossref_primary_10_3390_ijms241814270 crossref_primary_10_3390_cancers12113150 crossref_primary_10_1016_j_matchemphys_2020_122841 crossref_primary_10_3390_pr11041277 crossref_primary_10_2478_ahem_2022_0013 crossref_primary_10_20324_nelumbo_v65_2023_173240 crossref_primary_10_3390_ph15111306 crossref_primary_10_2174_1871520621666210903122831 crossref_primary_10_1016_j_maturitas_2016_11_012 crossref_primary_10_3390_molecules28114550 |
| Cites_doi | 10.3109/08923973.2012.738688 10.1038/35077213 10.3109/15563658408992565 10.3322/caac.21208 10.1007/BF02976663 10.3322/canjclin.57.1.43 10.1002/mc.20242 10.1007/s13277-014-2421-z 10.1007/s10585-005-4335-z 10.1126/science.270.5240.1326 10.1016/S0955-0674(98)80144-0 10.1038/371346a0 10.2307/3579638 10.1002/ijc.29154 10.1002/(SICI)1097-0215(20000115)85:2%3C176::AID-IJC5%3E3.0.CO;2-E 10.1158/1535-7163.MCT-05-0448 10.1016/j.tcb.2013.07.006 10.1074/jbc.M411383200 10.1073/pnas.1732912100 10.3322/canjclin.32.1.10 10.2174/1566524033479483 10.1248/bpb.29.1597 10.1016/j.jecm.2013.04.001 10.1371/journal.pone.0110244 10.1016/j.carbpol.2012.05.073 |
| ContentType | Journal Article |
| Copyright | Copyright © 2016, The Korean Society of Applied Pharmacology 2016 |
| Copyright_xml | – notice: Copyright © 2016, The Korean Society of Applied Pharmacology 2016 |
| DBID | AAYXX CITATION NPM 7X8 5PM ACYCR |
| DOI | 10.4062/biomolther.2015.172 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Korean Citation Index |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 1976-9148 2005-4483 |
| EndPage | 66 |
| ExternalDocumentID | oai_kci_go_kr_ARTI_199764 PMC4703354 26759703 10_4062_biomolther_2015_172 |
| Genre | Journal Article |
| GroupedDBID | --- 23N 5-W 5GY 8JR 9ZL AAYXX ADBBV ADRAZ AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CITATION DIK DU5 EF. F5P HYE HZB JDI KQ8 M48 OK1 PGMZT RPM NPM 7X8 5PM .UV ACYCR |
| ID | FETCH-LOGICAL-c438t-f8bed420a303543e3c895b405ed0b176f25b80584a698b562a29a4121f461aa23 |
| IEDL.DBID | M48 |
| ISSN | 2005-4483 1976-9148 |
| IngestDate | Tue Nov 21 21:34:48 EST 2023 Thu Aug 21 14:10:44 EDT 2025 Wed Oct 01 13:49:35 EDT 2025 Thu Apr 03 07:06:24 EDT 2025 Thu Apr 24 22:51:50 EDT 2025 Tue Jul 01 04:15:27 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Breast cancer Adhesion Amygdalin Apoptosis |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c438t-f8bed420a303543e3c895b405ed0b176f25b80584a698b562a29a4121f461aa23 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 G704-000363.2016.24.1.006 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.4062/biomolther.2015.172 |
| PMID | 26759703 |
| PQID | 1760875508 |
| PQPubID | 23479 |
| PageCount | 5 |
| ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_199764 pubmedcentral_primary_oai_pubmedcentral_nih_gov_4703354 proquest_miscellaneous_1760875508 pubmed_primary_26759703 crossref_citationtrail_10_4062_biomolther_2015_172 crossref_primary_10_4062_biomolther_2015_172 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2016-01-01 2016-Jan 20160101 2016-01 |
| PublicationDateYYYYMMDD | 2016-01-01 |
| PublicationDate_xml | – month: 01 year: 2016 text: 2016-01-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Korea (South) |
| PublicationPlace_xml | – name: Korea (South) |
| PublicationTitle | Biomolecules & therapeutics |
| PublicationTitleAlternate | Biomol Ther (Seoul) |
| PublicationYear | 2016 |
| Publisher | The Korean Society of Applied Pharmacology 한국응용약물학회 |
| Publisher_xml | – name: The Korean Society of Applied Pharmacology – name: 한국응용약물학회 |
| References | (OOOMB4_2016_v24n1_62_001) 1993; 68 (OOOMB4_2016_v24n1_62_014) 2011; 16 (OOOMB4_2016_v24n1_62_034) 2012; 90 (OOOMB4_2016_v24n1_62_020) 2006; 5 (OOOMB4_2016_v24n1_62_023) 2000; 85 (OOOMB4_2016_v24n1_62_006) 1994; 40 (OOOMB4_2016_v24n1_62_013) 1998; 10 (OOOMB4_2016_v24n1_62_028) 2014; 10 (OOOMB4_2016_v24n1_62_027) 2014; 64 (OOOMB4_2016_v24n1_62_011) 1982; 32 (OOOMB4_2016_v24n1_62_031) 2003; 3 (OOOMB4_2016_v24n1_62_004) 2006; 29 (OOOMB4_2016_v24n1_62_029) 2003; 100 (OOOMB4_2016_v24n1_62_033) 1995; 270 (OOOMB4_2016_v24n1_62_002) 2014; 35 (OOOMB4_2016_v24n1_62_018) 1994; 371 (OOOMB4_2016_v24n1_62_016) 2015; 136 (OOOMB4_2016_v24n1_62_009) 2013; 23 (OOOMB4_2016_v24n1_62_025) 1999; 59 (OOOMB4_2016_v24n1_62_015) 2007; 57 (OOOMB4_2016_v24n1_62_007) 1998; 150 (OOOMB4_2016_v24n1_62_003) 2012; 2012 (OOOMB4_2016_v24n1_62_017) 2003; 26 (OOOMB4_2016_v24n1_62_032) 2006; 45 (OOOMB4_2016_v24n1_62_012) 1984; 22 (OOOMB4_2016_v24n1_62_005) 2013; 35 (OOOMB4_2016_v24n1_62_008) 2001; 411 (OOOMB4_2016_v24n1_62_010) 2005; 22 (OOOMB4_2016_v24n1_62_019) 2014; 9 (OOOMB4_2016_v24n1_62_026) 2014; 25 (OOOMB4_2016_v24n1_62_021) 2005; 280 (OOOMB4_2016_v24n1_62_030) 2013; 5 (OOOMB4_2016_v24n1_62_024) 2015; 8 24751072 - Carbohydr Polym. 2012 Sep 1;90(1):516-23 22071824 - Cochrane Database Syst Rev. 2011 Nov 09;(11):CD005476 8090205 - Nature. 1994 Sep 22;371(6495):346-7 10629074 - Int J Cancer. 2000 Jan 15;85(2):176-81 21278435 - Oncologist. 2011;16 Suppl 1:1-11 8423675 - Lab Invest. 1993 Jan;68(1):4-17 12917485 - Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10393-8 6275965 - CA Cancer J Clin. 1982 Jan-Feb;32(1):10-4 9561846 - Curr Opin Cell Biol. 1998 Apr;10(2):220-31 16705745 - Mol Carcinog. 2006 Oct;45(10):795-804 12643594 - Arch Pharm Res. 2003 Feb;26(2):157-61 25155634 - Int J Cancer. 2015 Mar 15;136(6):E508-20 23958396 - Trends Cell Biol. 2013 Dec;23(12):620-33 7787878 - Cell Mol Biol Res. 1994;40(7-8):603-12 6098693 - J Toxicol Clin Toxicol. 1984;22(4):341-7 10344758 - Cancer Res. 1999 May 15;59(10):2457-63 11357141 - Nature. 2001 May 17;411(6835):342-8 22505933 - Int J Cell Biol. 2012;2012:676731 25333694 - PLoS One. 2014 Oct 15;9(10):e110244 26191238 - Int J Clin Exp Pathol. 2015 May 01;8(5):5363-70 25207888 - J Cancer Res Ther. 2014 Aug;10 Suppl 1:3-7 16880611 - Biol Pharm Bull. 2006 Aug;29(8):1597-602 24115144 - Phytochem Anal. 2014 Mar-Apr;25(2):122-6 16505103 - Mol Cancer Ther. 2006 Feb;5(2):296-308 15536074 - J Biol Chem. 2005 Jan 14;280(2):923-32 14601637 - Curr Mol Med. 2003 Nov;3(7):631-42 7481820 - Science. 1995 Nov 24;270(5240):1326-31 25104089 - Tumour Biol. 2014 Sep;35(9):8483-523 17237035 - CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 24399786 - CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29 23137229 - Immunopharmacol Immunotoxicol. 2013 Feb;35(1):43-51 9650595 - Radiat Res. 1998 Jul;150(1):3-10 16086230 - Clin Exp Metastasis. 2005;22(2):99-106 |
| References_xml | – volume: 16 start-page: 1 year: 2011 ident: OOOMB4_2016_v24n1_62_014 publication-title: Oncologist – volume: 35 start-page: 43 year: 2013 ident: OOOMB4_2016_v24n1_62_005 publication-title: Immunopharmacol. Immunotoxicol. doi: 10.3109/08923973.2012.738688 – volume: 411 start-page: 342 year: 2001 ident: OOOMB4_2016_v24n1_62_008 publication-title: Nature doi: 10.1038/35077213 – volume: 22 start-page: 341 year: 1984 ident: OOOMB4_2016_v24n1_62_012 publication-title: J. Toxicol. Clin. Toxicol. doi: 10.3109/15563658408992565 – volume: 64 start-page: 9 year: 2014 ident: OOOMB4_2016_v24n1_62_027 publication-title: CA Cancer. J. Clin. doi: 10.3322/caac.21208 – volume: 26 start-page: 157 year: 2003 ident: OOOMB4_2016_v24n1_62_017 publication-title: Arch. Pharm. Res. doi: 10.1007/BF02976663 – volume: 57 start-page: 43 year: 2007 ident: OOOMB4_2016_v24n1_62_015 publication-title: CA Cancer J. Clin. doi: 10.3322/canjclin.57.1.43 – volume: 8 start-page: 5363 year: 2015 ident: OOOMB4_2016_v24n1_62_024 publication-title: Int. J. Clin. Exp. Pathol. – volume: 45 start-page: 795 year: 2006 ident: OOOMB4_2016_v24n1_62_032 publication-title: Mol. Carcinog. doi: 10.1002/mc.20242 – volume: 35 start-page: 8483 year: 2014 ident: OOOMB4_2016_v24n1_62_002 publication-title: Tumour Biol doi: 10.1007/s13277-014-2421-z – volume: 22 start-page: 99 year: 2005 ident: OOOMB4_2016_v24n1_62_010 publication-title: Clin. Exp. Metastasis doi: 10.1007/s10585-005-4335-z – volume: 25 start-page: 122126 year: 2014 ident: OOOMB4_2016_v24n1_62_026 publication-title: Phytochem. Anal. – volume: 270 start-page: 1326 year: 1995 ident: OOOMB4_2016_v24n1_62_033 publication-title: Science doi: 10.1126/science.270.5240.1326 – volume: 68 start-page: 4 year: 1993 ident: OOOMB4_2016_v24n1_62_001 publication-title: Lab. Invest. – volume: 10 start-page: 220 year: 1998 ident: OOOMB4_2016_v24n1_62_013 publication-title: Curr. Opin. Cell Biol. doi: 10.1016/S0955-0674(98)80144-0 – volume: 371 start-page: 346 year: 1994 ident: OOOMB4_2016_v24n1_62_018 publication-title: Nature doi: 10.1038/371346a0 – volume: 150 start-page: 3 year: 1998 ident: OOOMB4_2016_v24n1_62_007 publication-title: Radiat. Res doi: 10.2307/3579638 – volume: 136 start-page: E508 year: 2015 ident: OOOMB4_2016_v24n1_62_016 publication-title: Int. J. Cancer doi: 10.1002/ijc.29154 – volume: 85 start-page: 176 year: 2000 ident: OOOMB4_2016_v24n1_62_023 publication-title: Int. J. Cancer doi: 10.1002/(SICI)1097-0215(20000115)85:2%3C176::AID-IJC5%3E3.0.CO;2-E – volume: 5 start-page: 296 year: 2006 ident: OOOMB4_2016_v24n1_62_020 publication-title: Mol. Cancer Ther doi: 10.1158/1535-7163.MCT-05-0448 – volume: 23 start-page: 620 year: 2013 ident: OOOMB4_2016_v24n1_62_009 publication-title: Trends Cell Biol doi: 10.1016/j.tcb.2013.07.006 – volume: 280 start-page: 923 year: 2005 ident: OOOMB4_2016_v24n1_62_021 publication-title: J. Biol. Chem. doi: 10.1074/jbc.M411383200 – volume: 59 start-page: 2457 year: 1999 ident: OOOMB4_2016_v24n1_62_025 publication-title: Cancer Res – volume: 2012 start-page: 676 year: 2012 ident: OOOMB4_2016_v24n1_62_003 publication-title: Int. J. Cell Biol. – volume: 100 start-page: 10393 year: 2003 ident: OOOMB4_2016_v24n1_62_029 publication-title: Proc. Natl. Acad. Sci. U.S.A. doi: 10.1073/pnas.1732912100 – volume: 32 start-page: 10 year: 1982 ident: OOOMB4_2016_v24n1_62_011 publication-title: CA Cancer J. Clin. doi: 10.3322/canjclin.32.1.10 – volume: 40 start-page: 603 year: 1994 ident: OOOMB4_2016_v24n1_62_006 publication-title: Cell. Mol. Biol. Res. – volume: 3 start-page: 631 year: 2003 ident: OOOMB4_2016_v24n1_62_031 publication-title: Curr. Mol. Med. doi: 10.2174/1566524033479483 – volume: 29 start-page: 1597 year: 2006 ident: OOOMB4_2016_v24n1_62_004 publication-title: Biol. Pharm. Bull. doi: 10.1248/bpb.29.1597 – volume: 10 start-page: 3 year: 2014 ident: OOOMB4_2016_v24n1_62_028 publication-title: J. Cancer Res. Ther. – volume: 5 start-page: 89 year: 2013 ident: OOOMB4_2016_v24n1_62_030 publication-title: J. Exp. Clin. Med. doi: 10.1016/j.jecm.2013.04.001 – volume: 9 start-page: e110244 year: 2014 ident: OOOMB4_2016_v24n1_62_019 publication-title: PLoS One doi: 10.1371/journal.pone.0110244 – volume: 90 start-page: 516 year: 2012 ident: OOOMB4_2016_v24n1_62_034 publication-title: Carbohydr. Polym. doi: 10.1016/j.carbpol.2012.05.073 – reference: 7481820 - Science. 1995 Nov 24;270(5240):1326-31 – reference: 9650595 - Radiat Res. 1998 Jul;150(1):3-10 – reference: 12643594 - Arch Pharm Res. 2003 Feb;26(2):157-61 – reference: 24399786 - CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29 – reference: 11357141 - Nature. 2001 May 17;411(6835):342-8 – reference: 14601637 - Curr Mol Med. 2003 Nov;3(7):631-42 – reference: 7787878 - Cell Mol Biol Res. 1994;40(7-8):603-12 – reference: 15536074 - J Biol Chem. 2005 Jan 14;280(2):923-32 – reference: 12917485 - Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10393-8 – reference: 21278435 - Oncologist. 2011;16 Suppl 1:1-11 – reference: 23958396 - Trends Cell Biol. 2013 Dec;23(12):620-33 – reference: 16505103 - Mol Cancer Ther. 2006 Feb;5(2):296-308 – reference: 8090205 - Nature. 1994 Sep 22;371(6495):346-7 – reference: 25104089 - Tumour Biol. 2014 Sep;35(9):8483-523 – reference: 24751072 - Carbohydr Polym. 2012 Sep 1;90(1):516-23 – reference: 6098693 - J Toxicol Clin Toxicol. 1984;22(4):341-7 – reference: 10344758 - Cancer Res. 1999 May 15;59(10):2457-63 – reference: 17237035 - CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 – reference: 25333694 - PLoS One. 2014 Oct 15;9(10):e110244 – reference: 16705745 - Mol Carcinog. 2006 Oct;45(10):795-804 – reference: 25155634 - Int J Cancer. 2015 Mar 15;136(6):E508-20 – reference: 16880611 - Biol Pharm Bull. 2006 Aug;29(8):1597-602 – reference: 23137229 - Immunopharmacol Immunotoxicol. 2013 Feb;35(1):43-51 – reference: 22505933 - Int J Cell Biol. 2012;2012:676731 – reference: 22071824 - Cochrane Database Syst Rev. 2011 Nov 09;(11):CD005476 – reference: 10629074 - Int J Cancer. 2000 Jan 15;85(2):176-81 – reference: 8423675 - Lab Invest. 1993 Jan;68(1):4-17 – reference: 26191238 - Int J Clin Exp Pathol. 2015 May 01;8(5):5363-70 – reference: 6275965 - CA Cancer J Clin. 1982 Jan-Feb;32(1):10-4 – reference: 25207888 - J Cancer Res Ther. 2014 Aug;10 Suppl 1:3-7 – reference: 9561846 - Curr Opin Cell Biol. 1998 Apr;10(2):220-31 – reference: 16086230 - Clin Exp Metastasis. 2005;22(2):99-106 – reference: 24115144 - Phytochem Anal. 2014 Mar-Apr;25(2):122-6 |
| SSID | ssj0067156 |
| Score | 2.3449726 |
| Snippet | Amygdalin, D-mandelonitrile-β-D-glucoside-6-β-glucoside, belongs to aromatic cyanogenic glycoside group derived from rosaceous plant seed. Mounting evidence... |
| SourceID | nrf pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 62 |
| SubjectTerms | Original 약학 |
| Title | Amygdalin Regulates Apoptosis and Adhesion in Hs578T Triple-Negative Breast Cancer Cells |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/26759703 https://www.proquest.com/docview/1760875508 https://pubmed.ncbi.nlm.nih.gov/PMC4703354 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002060567 |
| Volume | 24 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Biomolecules & Therapeutics, 2016, 24(1), , pp.62-66 |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Colorado Digital library customDbUrl: eissn: 1976-9148 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0067156 issn: 2005-4483 databaseCode: KQ8 dateStart: 20120101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1976-9148 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0067156 issn: 2005-4483 databaseCode: DIK dateStart: 20080101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVERR databaseName: [Open Access] KoreaMed customDbUrl: eissn: 1976-9148 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0067156 issn: 2005-4483 databaseCode: 5-W dateStart: 20130101 isFulltext: true titleUrlDefault: https://koreamed.org/journals providerName: Korean Association of Medical Journal Editors – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1976-9148 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0067156 issn: 2005-4483 databaseCode: RPM dateStart: 20120101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 1976-9148 dateEnd: 20250930 omitProxy: true ssIdentifier: ssj0067156 issn: 2005-4483 databaseCode: M48 dateStart: 20120101 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT-MwELZ4XLggEK_CgozEkZQkdRzntCoVqCDBAbVSb5ad2KUiJCUJ0vLvd6ZJykPAKYf4ocyMNd-MJ98QcmY5S3SYAHKLXeMwz_qOVoo5XHtI_iIibjGhf3fPh2N2OwkmK6TtitoIsPw2tMN-UuMi7f57efsLBx7waxfckX-BP6rnKeIlLNUKuuCTV8k6uCYfzfyOLa8VeOgt2rl64IPhlDNR0xD9tAgSBQOejsK2o1bjtVazwn4HSL_WVX5wVNdbZLNBmLRfm8Q2WTHZDpn0n9-mCWDujD7U3edNSfvzfF7l5aykKktoP3k0mDqjMGYIjlSM6KjANLxzb6YLenB6iRXsFR2gpRR0YNK03CXj66vRYOg0TRWcmPVE5VihTcJ8V4HvCljP9GIRBRpgm0lc7YWgmkALF2CJ4pHQgI6UHykQpWcZ95Tye3tkLcszc0CoyxPPQrjkGwFBZai1AdXymHHXaCas7RC_FZqMG8ZxbHyRSog8UOjyXegShS5B6B1yvpw0rwk3fh9-CtqQT_FMIlE2Pqe5fCokhAM3EqtoOIMxra4kHB68EVGZyV9LWIAjoz-A1A7Zr3W33LRVfYeEn7S6HID7fX6TzR4XBN0MpoFwD39c84hswAc0qZw_ZK0qXs0xgJtKnywM9j_6_vc4 |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Amygdalin+Regulates+Apoptosis+and+Adhesion+in+Hs578T+Triple-Negative+Breast+Cancer+Cells&rft.jtitle=Biomolecules+%26+therapeutics&rft.au=Lee%2C+Hye+Min&rft.au=Moon%2C+Aree&rft.date=2016-01-01&rft.issn=1976-9148&rft.volume=24&rft.issue=1&rft.spage=62&rft_id=info:doi/10.4062%2Fbiomolther.2015.172&rft_id=info%3Apmid%2F26759703&rft.externalDocID=26759703 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2005-4483&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2005-4483&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2005-4483&client=summon |